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A BS TR AC T 
BACKGROUND
The course of autosomal dominant polycystic kidney disease (ADPKD) is often associ-
ated with pain, hypertension, and kidney failure. Preclinical studies indicated that 
vasopressin V2-receptor antagonists inhibit cyst growth and slow the decline of kidney 
function.
METHODS
In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we ran-
domly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total 
kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per 
minute or more, in a 2:1 ratio to receive tolvaptan, a V2-receptor antagonist, at the high-
est of three twice-daily dose regimens that the patient found tolerable, or placebo. 
The primary outcome was the annual rate of change in the total kidney volume. 
Sequential secondary end points included a composite of time to clinical progression 
(defined as worsening kidney function, kidney pain, hypertension, and albuminuria) 
and rate of kidney-function decline.
RESULTS
Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 
2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the 
placebo group (95% CI, 5.1 to 6.0; P<0.001). The composite end point favored 
tolvaptan over placebo (44 vs. 50 events per 100 follow-up-years, P = 0.01), with lower 
rates of worsening kidney function (2 vs. 5 events per 100 person-years of follow-
up, P<0.001) and kidney pain (5 vs. 7 events per 100 person-years of follow-up, 
P = 0.007). Tolvaptan was associated with a slower decline in kidney function (recip-
rocal of the serum creatinine level, −2.61 [mg per milliliter]−1 per year vs. −3.81 [mg per 
milliliter]−1 per year; P<0.001). There were fewer ADPKD-related adverse events in the 
tolvaptan group but more events related to aquaresis (excretion of electrolyte-free 
water) and hepatic adverse events unrelated to ADPKD, contributing to a higher dis-
continuation rate (23%, vs. 14% in the placebo group).
CONCLUSIONS
Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and 
the decline in kidney function over a 3-year period in patients with ADPKD but was 
associated with a higher discontinuation rate, owing to adverse events. (Funded by 
Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercial-
ization; TEMPO 3:4 ClinicalTrials.gov number, NCT00428948.)
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A utosomal dominant polycystic kid-ney disease (ADPKD) is the most common monogenic kidney disease and the fourth 
leading cause of end-stage kidney disease in adults 
worldwide.1,2 It results in the progressive devel-
opment of kidney cysts, kidney pain, hypertension, 
and, ultimately, kidney failure. Effective treatment 
for ADPKD has been lacking.
Studies of animal models implicate the antidi-
uretic hormone arginine vasopressin and its sec-
ond messenger adenosine-3′,5′-cyclic monophos-
phate (cAMP) as promoters of kidney-cyst cell 
proliferation and luminal fluid secretion. The sup-
pression of vasopressin release by means of high 
water intake, genetic elimination of vasopressin, 
and vasopressin V2-receptor blockade all reduce 
the cyst burden and protect kidney function.3-9 
Such preclinical studies justify studying the effects 
of tolvaptan, a vasopressin V2-receptor antago-
nist,10 in human ADPKD. Tolvaptan is approved 
for the treatment of dilutional hyponatremia (in 
various countries) or volume overload in heart 
failure (in Japan).
In 3-year, open-label clinical trials involving 
63 patients with ADPKD as compared with his-
torical controls, tolvaptan slowed the increase in 
total kidney volume (1.7% vs. 5.8% per year, 
P<0.001) and the decline in the estimated glo-
merular filtration rate (GFR; −0.71 vs. −2.1 ml per 
minute per 1.73 m2 of body-surface area per 
year, P = 0.01).11 Limitations of these studies in-
cluded the small number of patients, noncontem-
porary controls, and unmatched ethnic groups. 
Here we report the results of the Tolvaptan Ef-
ficacy and Safety in Management of Autosomal 
Dominant Polycystic Kidney Disease and Its Out-
comes (TEMPO) 3:4 trial, a phase 3, multicenter, 
randomized, double-blind, placebo-controlled, 
parallel-group trial.12
ME THODS
TRIAL DESIGN AND OVERSIGHT
We enrolled patients at 129 sites worldwide from 
January 2007 through January 2009. Eligible per-
sons were from 18 to 50 years of age, with a diag-
nosis of ADPKD (see the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org),13 a total kidney volume of 750 ml or 
more14,15 as measured with the use of magnetic 
resonance imaging (MRI), and a creatinine clear-
ance of 60 ml per minute or more as estimated by 
means of the Cockcroft–Gault formula.16 Random-
ization was carried out centrally, with patients 
randomly assigned in a 2:1 ratio to receive tolvap-
tan or placebo and with stratification according to 
hypertension status (present vs. absent), creatinine 
clearance (<80 vs. ≥80 ml per minute), total kid-
ney volume (<1000 vs. ≥1000 ml), and geograph-
ic area.12
Tolvaptan dosing was started in daily morning 
and afternoon doses of 45 mg and 15 mg, respec-
tively, with weekly increases to 60 mg and 30 mg 
and then to 90 mg and 30 mg, according to 
patient-reported tolerability. For 36 months, pa-
tients took the highest dose that they reported as 
tolerable. Patients who reported that they could 
not tolerate the lowest dose were asked to con-
tinue follow-up by telephone. Adherence to treat-
ment was self-reported and confirmed by means 
of pill counts. The use of diuretics and drugs in-
hibiting the cytochrome P-450 enzyme CYP3A4 
was avoided, given their effects on urine output 
and tolvaptan blood levels, respectively.
The institutional review board or ethics com-
mittee at each site approved the protocol; written 
informed consent was obtained from all partici-
pants. A steering committee of investigators and 
representatives of the sponsor, Otsuka Pharmaceu-
ticals, oversaw the trial design and conduct with 
the assistance of the independent data and safety 
monitoring committee and the clinical event com-
mittee. The sponsor collected and analyzed the 
data. The first author assumes responsibility for 
the overall content and integrity of the manuscript, 
with substantial contributions from the coauthors, 
who all had access to the data and jointly de-
cided to submit the manuscript for publication. 
All authors vouch for the accuracy and complete-
ness of the reported data, as well as the fidelity of 
this report to the protocol. The protocol is available 
at NEJM.org and has been published previously.12
TRIAL ASSESSMENTS
Evaluations were performed at baseline, at random-
ization, weekly during the dose-escalation phase, 
every 4 months (monthly in Japan) during treat-
ment, and twice between 1 and 6 weeks (with the 
visits at least 1 week apart) after the completion 
of treatment at 36 months. Evaluations included 
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physical examination, assessment of vital signs, 
electrocardiography, and blood and urine tests. 
The serum creatinine level was measured centrally 
with the use of the IDMS-traceable Roche enzy-
matic method and was reported to two decimal 
points.17 Standardized MRI scans of the kidneys 
were obtained, as described in the protocol, at base-
line and at months 12, 24, and 36 (±2 weeks); for 
patients who did not complete the study, the final 
MRI scans were obtained within 2 weeks before 
or after withdrawal if they had not been acquired 
during the previous 6 months.
OUTCOME MEASURES
The primary end point was the annual rate of 
percentage change in total kidney volume. The 
composite secondary end point was the time to 
investigator-assessed clinical progression, defined 
as worsening kidney function (a 25% reduction in 
the reciprocal of the serum creatinine level from 
the value at the end of the dose-adjustment peri-
od, reproduced after at least 2 weeks); clinically 
significant kidney pain necessitating medical leave, 
pharmacologic treatment (narcotic or last-resort 
analgesic agents), or invasive intervention; wors-
ening hypertension (changes in blood-pressure cat-
egory, as defined in the protocol, or worsening of 
hypertension requiring an increase in hypertensive 
treatment); and worsening albuminuria (according 
to sex-specified categories as defined in the pro-
tocol). These events were further adjudicated by an 
independent clinical events committee for a sen-
sitivity analysis.
The next secondary end point was the change 
in the slope of kidney function as measured by the 
reciprocal of the serum creatinine level.18 The re-
ciprocal of the serum creatinine level has a linear 
relationship with the GFR, unlike the serum cre-
atinine level, which has a curvilinear relationship. 
These values, expressed as (mg per milliliter)−1, 
approximate GFR values, with which clinicians are 
familiar. Other secondary end points are outlined 
in the protocol12 and in the Supplementary Ap-
pendix. Equations from the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) 
that are adjusted for ethnic group were used to 
determine the estimated GFR.17,19 Kidney-func-
tion end points were analyzed during treatment, 
with the use of measurements obtained at the 
end of the dose-escalation period and at the last 
treatment visit, since tolvaptan reversibly increases 
the serum creatinine level.11,20,21 Sensitivity anal-
yses that included data obtained before and after 
treatment were used to confirm the results ob-
tained during treatment.
STATISTICAL ANALYSIS
Using Lefante’s formula,22 we calculated that we 
would need to enroll 600 patients, assuming stan-
dard deviations for total noise and the slope across 
patients of 0.017 and 0.018 (in log10 scale), respec-
tively; an average untreated increase in the growth 
rate for total kidney volume of 7%; 85% power to 
detect a 20% reduction in the rate of growth; a two-
sided alpha level of 0.045; and a 20% withdrawal 
rate. We doubled this estimated sample size, for a 
target enrollment of 1200 to 1500 patients, to pro-
vide robust statistical power for the primary and 
composite secondary end points in a single trial.
Details of the analysis are available in the pro-
tocol.12 For the analysis of the primary end point, 
we compared individual slopes for total kidney 
volume between the groups, by fitting the log10-
transformed data on total kidney volume to a lin-
ear mixed-effects Laird–Ware model.23 Antilog 
(with a base of 10) of the treatment effect and 95% 
confidence intervals derived from the model (in a 
log10 scale) provide a ratio of geometric means of 
the slope of total kidney volume (i.e., 100% plus 
annual percentage change). A mixed-model re-
peated-measures analysis was applied to the re-
peated measures of change from baseline in log10-
transformed data on total kidney volume as a 
sensitivity analysis.
The analysis of the composite secondary end 
point was performed with the use of the Ander-
sen–Gill approach for the extended Cox model, for 
analysis of time to multiple events. The P value 
was provided by the Wald test with the use of a 
sandwich estimate of the covariance matrix. 
Treatment was the sole variable in the model.24 
Data were censored when patients withdrew from 
the trial. The analysis of the slope of kidney-
function decline was similar to the analysis of the 
slope of the total kidney volume.
The primary analyses of all efficacy end points 
were prespecified as intention-to-treat analyses of 
data obtained during the treatment period, with 
sensitivity analyses that included pretreatment and 
post-treatment data in the intention-to-treat pop-
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ulation. Study end points were ordered hierarchi-
cally and tested sequentially with the use of gate-
keeping procedures. For informational purposes, 
confidence intervals and P values are provided for 
subsequent comparisons and sensitivity analyses.
R ESULT S
PATIENTS
We screened 2122 patients, of whom 1445 were 
randomly assigned to either tolvaptan (961 pa-
tients) or placebo (484, with 1 patient withdraw-
ing after randomization and before receiving any 
study medication) (Fig. 1). Overall, 1157 patients 
(80.1%) completed the 3-year trial (77.0% of the 
patients in the tolvaptan group [2335 exposure-
years] and 86.2% of those in the placebo group 
[1306 exposure-years]). Nearly half the patients 
who permanently discontinued the study drug — 
46% in the tolvaptan group and 40% in the pla-
cebo group — agreed to telephone follow-up. The 
primary efficacy analysis included 1307 of the 
1445 patients (90.4%), with 138 patients excluded 
because of early withdrawal and a lack of mea-
surable follow-up MRI scans. All 1445 patients 
(100%) were included in the key secondary effi-
cacy analysis, and 1444 (99.9%) were included in 
the key secondary safety analysis. Demographic 
and baseline characteristics in the two groups were 
well balanced (Table 1).
ADHERENCE TO TREATMENT 
Adherence exceeded 90% in 845 of the 961 patients 
in the tolvaptan group (88%), with an average 
dose of 95 mg per day, and in 451 of the 483 pa-
tients in the placebo group (93%), with an average 
sham dose of 110 mg per day. Of the patients who 
completed 36 months of treatment with tolvaptan, 
404 (55%) took the high dose (a total daily dose of 
120 mg), whereas 157 (21%) and 179 (24%) took the 
middle dose (90 mg) and low dose (60 mg), respec-
tively. Of the patients who completed 36 months 
of placebo treatment, 348 (83%), 38 (9%), and 32 
(8%) took the corresponding sham doses.
PRIMARY END POINT
Over the 3-year period, total kidney volume in-
creased by 2.8% per year (95% confidence inter-
val [CI], 2.5 to 3.1) with tolvaptan versus 5.5% per 
year (95% CI, 5.1 to 6.0) with placebo. Tolvaptan 
changed the rate of growth by −2.7 percentage 
points per year (95% CI, −3.3 to −2.1); the ratio of 
the geometric means of growth rate was 0.97 
(95% CI, 0.97 to 0.98; P<0.001) (Fig. 2A).
The mixed-model repeated-measures analysis 
confirmed the analysis of the primary end point 
(least-squares mean change in total kidney vol-
ume over the 3-year period, 9.56% with tolvap-
tan vs. 18.75% with placebo). This difference of 
−9.2 percentage points (95% CI, −11.1 to −7.3; 
P<0.001) represents a treatment effect of 49.2% 
in the intention-to-treat population, with a larger 
effect observed during the first year than during 
the second and third years (Tables S1 and S2 and 
Fig. S1 in the Supplementary Appendix). This same 
analysis, when restricted to patients who were 
taking the trial drug at the time of image acqui-
sition, showed a higher between-group difference 
during the third year (Tables S1 and S2 and Fig. 
S1 in the Supplementary Appendix).
Prespecified subgroup analysis showed that 
tolvaptan had a beneficial effect on total kidney 
volume in all subgroups, with patients stratified 
according to sex, age (<35 years vs. ≥35 years), 
total kidney volume at baseline (<1500 ml vs. 
≥1500 ml), estimated creatinine clearance level 
at baseline (<80 ml per minute vs. ≥80 ml per 
minute), and hypertension status (absent vs. pres-
ent) (Fig. 2B).
SECONDARY END POINTS
Slope of Kidney Function
The first noncomposite secondary end point, the 
slope of kidney function (as assessed by means of 
the reciprocal of the serum creatinine level) from 
the end of dose escalation to month 36, also fa-
vored tolvaptan, with a slope of −2.61 (mg per 
milliliter)−1 per year, as compared with −3.81 (mg 
per milliliter)−1 per year with placebo; the treat-
ment effect was an increase of 1.20 (mg per mil-
liliter)−1 per year (95% CI, 0.62 to 1.78; P<0.001) 
(Fig. 2C). This treatment effect was confirmed by 
comparing data from pretreatment baseline and 
post-treatment visits, which showed an increase of 
4.93 (mg per milliliter)−1 over the 3-year period for 
tolvaptan, as compared with placebo (P<0.001). 
This corresponds to an increase in the mean serum 
creatinine level from 1.05 mg per deciliter (93 μmol 
per liter) to 1.21 mg per deciliter (107 μmol per 
liter) in the tolvaptan group, as compared with 
an increase from 1.04 mg per deciliter (92 μmol 
per liter) to 1.27 mg per deciliter (112 μmol per 
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liter) in the placebo group (mean difference, 
−0.09 mg per deciliter [−8 μmol per liter]; 95% CI, 
−0.13 to −0.06 [−11 to −5]; P<0.001).
The mixed-model repeated-measures analysis 
showed a significant benefit of tolvaptan begin-
ning at year 1 (between-group difference, 2.02 [mg 
per milliliter]−1; P<0.001) and increasing through 
year 3 (between-group difference, 3.68 [mg per 
milliliter]−1; P<0.001) (Table S3 in the Supple-
mentary Appendix). Analysis of the annual esti-
mated GFR slope gave results similar to those of 
the slopes of the reciprocal of the serum creati-
nine level, with an estimated GFR slope of −2.72 
ml per minute per 1.73 m2 per year in the tolvap-
tan group versus −3.70 in the placebo group (treat-
ment effect, an increase of 0.98 ml per minute 
per 1.73 m2 per year; 95% CI, 0.60 to 1.36; 
P<0.001) (Fig. S3 in the Supplementary Appendix).
1445 Underwent randomization
2122 Patients were assessed for eligibility
677 Were excluded
530 Did not meet inclusion criteria
45 Declined to participate
102 Had other reasons
961 Were assigned to receive tolvaptan
961 Received tolvaptan (safety population)
484 Were assigned to receive placebo
483 Received placebo (safety population)
1 Declined participation after randomization
221 Discontinued the study
148 (15.4%) Had adverse
events
50 (5.2%) Withdrew
consent
15 (1.6%) Were lost to
follow-up
4 (0.4%) Met withdrawal
criteria
3 (0.3%) Were withdrawn 
by the investigator
1 (0.1%) Had a protocol
deviation
67 Discontinued the study
24 (5.0%) Had adverse
events
30 (6.2%) Withdrew
consent
8 (1.7%) Were lost to
follow-up
4 (0.8%) Were withdrawn
by the investigator
1 (0.2%) Had a protocol
deviation
465 (96.1%) Were included in primary efficacy
analysis (had at least one MRI measurement
of total kidney volume after baseline)
484 (100%) Were included in key secondary analysis
483 (99.8%) Were included in safety analysis
842 (87.6%) Were included in primary efficacy
analysis (had at least one MRI measurement
of total kidney volume after baseline)
961 (100%) Were included in key secondary analysis
961 (100%) Were included in safety analysis
740 (77.0%) Completed the trial 417 (86.2%) Completed the trial
Figure 1. Patient Enrollment and Outcomes.
We screened 2122 patients, of whom 1445 were randomly assigned to receive either tolvaptan or placebo. Overall, 
1157 patients (80.1%) completed the 3-year trial. The primary efficacy analysis included 1307 of the 1445 patients 
(90.4%), the key secondary efficacy analysis included all 1445 (100%), and the key secondary safety analysis included 
1444 (99.9%). MRI denotes magnetic resonance imaging.
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Prespecified subgroup analysis suggested that 
tolvaptan had a beneficial effect on renal function 
in all stratification subgroups (Fig. 2D). However, 
these effects were nominally greater among pa-
tients 35 years of age or older and among those 
with hypertension or a total kidney volume of 
1500 ml or more.
Clinical Progression
Analysis of the key secondary composite end 
point, tested after the primary end point, showed 
fewer ADPKD-related events per 100 person-years 
of follow-up with tolvaptan than with placebo 
(44 vs. 50 events; hazard ratio, 0.87; 95% CI, 0.78 
to 0.97; P = 0.01) (Fig. 3A and 3B). This result was 
confirmed by the analysis of time to first event, 
with a hazard ratio of 0.83 (95% CI, 0.72 to 0.94; 
P = 0.005). An analysis of adjudicated events con-
firmed these results (hazard ratio, 0.85; 95% CI, 
0.76 to 0.95; P = 0.004). The outcome of the com-
posite end point was driven by effects on kidney-
function decline (2 events per 100 person-years 
of follow-up in the tolvaptan group vs. 5 in the 
placebo group; hazard ratio, 0.39; 95% CI, 0.26 to 
0.57; P<0.001) (Fig. 3C) and kidney pain (5 events 
per 100 person-years of follow-up in the tolvaptan 
group vs. 7 in the placebo group; hazard ratio, 
0.64; 95% CI, 0.47 to 0.89; P = 0.007) (Fig. 3D). No 
effect of treatment was detected with regard to 
hypertension or albuminuria events (Fig. 3A, and 
Fig. S2 in the Supplementary Appendix).
Other Secondary End Points
After the first three sequentially tested end points, 
all other prespecified end points did not differ 
significantly between the tolvaptan group and 
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic
Tolvaptan
(N = 961)
Placebo
(N = 484)
Male sex — no. (%) 495 (51.5) 251 (51.9)
Age — yr 39±7 39±7
Race — no. (%)†
White 810 (84.3) 408 (84.3)
Asian 121 (12.6) 62 (12.8)
Other 30 (3.1) 14 (2.9)
Stratification factor — no. (%)
Hypertension 765 (79.6) 382 (78.9)
Estimated creatinine clearance <80 ml/min 242 (25.2) 130 (26.9)
Total kidney volume <1000 ml 197 (20.5) 101 (20.9)
Medical history — no. (%)
Hematuria 338 (35.2) 164 (33.9)
Kidney pain 496 (51.6) 239 (49.4)
Nephrolithiasis 187 (19.5) 109 (22.5)
Urinary tract infection 290 (30.2) 164 (33.9)
Anemia 105 (10.9) 48 (9.9)
Proteinuria 233 (24.2) 116 (24.0)
Current medication — no. (%)
Angiotensin-converting–enzyme inhibitor 419 (43.6) 199 (41.1)
Angiotensin-receptor blocker 307 (31.9) 165 (34.1)
Angiotensin-converting–enzyme inhibitor, angiotensin- 
receptor blocker, or both
683 (71.1) 350 (72.3)
Beta-blocker 171 (17.8) 94 (19.4)
Calcium-channel blocker 180 (18.7) 104 (21.5)
Diuretic 32 (3.3) 14 (2.9)
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the placebo group (Table S4 in the Supplemen-
tary Appendix).
ADVERSE EVENTS
The rates of adverse events were similar in the 
tolvaptan group (97.9% of patients) and the pla-
cebo group (97.1%). Patients who received tolvap-
tan had a higher frequency of adverse events related 
to increased aquaresis (thirst, polyuria, nocturia, 
and polydipsia, as a result of the excretion of 
electrolyte-free water), whereas those who received 
placebo had higher frequencies of adverse events 
related to ADPKD (kidney pain, hematuria, uri-
nary tract infection, and back pain) (Table 2, and 
Table S5 in the Supplementary Appendix). Serious 
adverse events occurring in at least 0.5% of the 
patients in either group are summarized in Table 2. 
A greater proportion of patients who received 
tolvaptan had elevations of liver-enzyme levels. 
Serious adverse events associated with chest pain 
and headache were slightly more frequent in the 
tolvaptan group, but the only two episodes of 
myocardial infarction and the only episode of sub-
arachnoid hemorrhage occurred in the placebo 
group. No patients died during the trial.
A total of 23.0% of the patients who received 
tolvaptan and 13.8% of those who received pla-
cebo permanently discontinued the trial drug. 
Adverse events led to more discontinuations in 
the tolvaptan group than in the placebo group 
(15.4% of patients vs. 5.0%) (Fig. 1). Of the 961 
patients in the tolvaptan group, 8.3% and 1.2% 
discontinued the trial drug because of aquaresis-
related symptoms and liver-function abnormali-
ties, respectively.
LABORATORY AND CLINICAL DATA
Laboratory studies are summarized in Table S6 
in the Supplementary Appendix. Treatment with 
tolvaptan resulted in an increase in the mean se-
rum sodium level of less than 2.5 mmol per liter 
by the end of the dose-escalation period. This 
reached potentially clinically important levels (de-
fined as a value >150 mmol per liter at any visit) 
in 4.0% of the patients who received tolvaptan and 
in 1.4% of those who received placebo. Despite an 
increase in serum uric acid levels and in the fre-
quency of gout among patients in the tolvaptan 
group, as compared with those in the placebo 
group (2.9% vs. 1.4%), these events were not con-
Table 1. (Continued.)
Characteristic
Tolvaptan
(N = 961)
Placebo
(N = 484)
Height — cm 173.5±10.4 173.6±7.8
Weight — kg 79±18 79±18
Blood pressure — mm Hg
Systolic 128.6±13.5 128.3±13.5
Diastolic 82.5±9.9 82.5±9.3
Total kidney volume — ml 1705±921 1668±873
Height-adjusted total kidney volume — ml/m 979±515 958±483
Serum creatinine — mg/dl‡ 1.05±0.30 1.04±0.32
Reciprocal of serum creatinine — (mg/ml)−1 102.27±27.21 104.30±35.60
Estimated creatinine clearance — ml/min§ 104.08±32.76 103.80±35.60
Estimated GFR — ml/min/1.73 m2¶ 81.35±21.02 82.14±22.73
Urinary albumin-to-creatinine ratio‖ 7.2±14.3 8.6±21.7
* Plus–minus values are means ±SD. No significant between-group differences were found for any of the baseline charac-
teristics. GFR denotes glomerular filtration rate.
† Race was self-reported.
‡ To convert values for creatinine to micromoles per liter, multiply by 88.4.
§ The estimated creatinine clearance was measured with the use of the Cockcroft–Gault formula. 
¶ Estimated GFR was measured with the use of the Chronic Kidney Disease Epidemiology Collaboration equation adjusted 
for race.
‖ For the urinary albumin-to-creatinine ratio, albumin was measured in milligrams per deciliter and creatinine in millimoles 
per deciliter.
The New England Journal of Medicine 
Downloaded from nejm.org on November 24, 2016. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;25 nejm.org december 20, 20122414
C
K
id
ne
y 
Fu
nc
tio
n
A
To
ta
l K
id
ne
y 
V
ol
um
e
D
Tr
ea
tm
en
t E
ff
ec
t f
or
 K
id
ne
y 
Fu
nc
tio
n
B
Tr
ea
tm
en
t E
ff
ec
t f
or
 T
ot
al
 K
id
ne
y 
V
ol
um
e
Change in Total Kidney Volume
(%)
60 2040 0 −2
0
B
as
el
in
e
12
24
36
M
on
th
s
−1
1
0 P
la
ce
bo
B
et
te
r
To
lv
ap
ta
n
B
et
te
r
−4
−3
−2
Su
bg
ro
up
A
bs
ol
ut
e 
Tr
ea
tm
en
t
Ef
fe
ct
R
el
at
iv
e 
Tr
ea
tm
en
t
Ef
fe
ct
%
/y
r
%
A
nn
ua
l S
lo
pe
To
lv
ap
ta
n
D
iff
er
en
ce
 in
 a
nn
ua
l s
lo
pe
 (
%
/y
r)
Pl
ac
eb
o
P 
V
al
ue
Se
x M
al
e
Fe
m
al
e
A
ge <
35
 y
r
≥3
5 
yr
H
yp
er
te
ns
io
n
Ye
s
N
o
Es
tim
at
ed
 c
re
at
in
in
e
cl
ea
ra
nc
e
<8
0 
m
l/
m
in
≥8
0 
m
l/
m
in
To
ta
l k
id
ne
y 
vo
lu
m
e
<1
50
0 
m
l
≥1
50
0 
m
l
A
ll 
pa
tie
nt
s
37
.3
71
.1
28
.0
58
.2
50
.5
51
.2
57
.2
47
.5
48
.8
51
.1
49
.2
4.
15
1.
24
4.
37
2.
23
3.
01
1.
62
2.
27
2.
92
2.
24
3.
29
2.
80
6.
62
4.
29
6.
06
5.
34
6.
09
3.
32
5.
32
5.
56
4.
37
6.
74
5.
51
<0
.0
01
<0
.0
01
0.
02
  
<0
.0
01
<0
.0
01
0.
00
8
<0
.0
01
<0
.0
01
<0
.0
01
<0
.0
01
<0
.0
01
Change in Kidney Function
(reciprocal serum creatinine [mg/ml]
−1
)
40 020 −2
0
−4
0
B
as
el
in
e
8
12
16
20
28
32
4
24
36
M
on
th
s
2
3
Pl
ac
eb
o
B
et
te
r
To
lv
ap
ta
n
B
et
te
r
−1
0
1
Su
bg
ro
up
A
bs
ol
ut
e 
Tr
ea
tm
en
t
Ef
fe
ct
R
el
at
iv
e 
Tr
ea
tm
en
t
Ef
fe
ct
(m
g/
m
l)
–1
%
A
nn
ua
l S
lo
pe
To
lv
ap
ta
n
D
iff
er
en
ce
 in
 a
nn
ua
l s
lo
pe
 (
[m
g/
m
l]–
1 )
Pl
ac
eb
o
P 
V
al
ue
Se
x M
al
e
Fe
m
al
e
A
ge <
35
 y
r
≥3
5 
yr
H
yp
er
te
ns
io
n
Ye
s
N
o
Es
tim
at
ed
 c
re
at
in
in
e
cl
ea
ra
nc
e
<8
0 
m
l/
m
in
≥8
0 
m
l/
m
in
To
ta
l k
id
ne
y 
vo
lu
m
e
<1
50
0 
m
l
≥1
50
0 
m
l
A
ll 
pa
tie
nt
s
32
.1
30
.7
26
.5
30
.6
35
.0 9.
6
32
.0
29
.7
21
.7
36
.6
31
.6
−2
.3
7
−2
.8
5
−1
.9
3
−2
.8
4
−2
.7
2
−2
.0
9
−3
.6
9
−2
.2
1
−1
.9
7
−3
.2
4
−2
.6
1
−3
.4
9
−4
.1
1
−2
.6
2
−4
.0
9
−4
.1
9
−2
.3
1
−5
.4
3
−3
.1
4
−2
.5
2
−5
.1
1
−3
.8
1
<0
.0
01
0.
02
  
0.
19
  
<0
.0
01
<0
.0
01
0.
69
  
0.
01
  
0.
00
1
0.
10
  
<0
.0
01
<0
.0
01
To
lv
ap
ta
n
Pl
ac
eb
o
To
lv
ap
ta
n
Pl
ac
eb
o
The New England Journal of Medicine 
Downloaded from nejm.org on November 24, 2016. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
n engl j med 367;25 nejm.org december 20, 2012 2415
sidered to be severe, nor did they lead to serious 
adverse events or withdrawal from the trial.
More patients who received tolvaptan than 
those who received placebo (4.9% vs. 1.2%) had 
potentially clinically important elevations of ala-
nine aminotransferase, defined as a value that was 
more than 2.5 times the upper limit of the nor-
mal range at any trial visit. Fewer patients who 
received tolvaptan than those who received pla-
cebo (0.9% vs. 1.9%) had potentially clinically im-
portant increases in the bilirubin level, defined 
as a value that was more than 1.5 times the upper 
limit of the normal range. A review of central and 
local laboratory data from narrative reports of seri-
ous adverse events and events leading to with-
drawal from the study identified two patients in 
the tolvaptan group who had concurrent elevations 
in the alanine aminotransferase or aspartate ami-
notransferase level (>3 times the upper limit of the 
normal range) and the bilirubin level (>2 times the 
upper limit of the normal range). In all cases, 
the abnormalities either resolved during treatment 
or returned toward baseline values with drug 
interruption or withdrawal. No reports of persis-
tent sequelae were received. There were no sig-
nificant differences in mean body weight, sys-
tolic or diastolic blood pressure, or heart rate 
between the patients who received tolvaptan and 
those who received placebo.
DISCUSSION
The administration of tolvaptan for 36 months 
was associated with slowed kidney growth and 
functional decline and with a reduced frequency 
of ADPKD-related complications among patients 
with a large kidney volume but a relatively pre-
served GFR. The change in total kidney volume 
with tolvaptan, as compared with placebo, was 
more pronounced in the first year of treatment. 
An acute decrease in the secretion of cyst fluid 
probably contributed to this effect; this hypothe-
sis is supported by short-term trials of tolvaptan in 
which a 3 to 4% reduction in total kidney volume 
was observed at 1 to 3 weeks.20,21 The steadily 
accumulating benefit observed with tolvaptan in 
years 2 and 3 is consistent with the inhibition 
of cyst-cell proliferation, as shown in animal 
and ex vivo human models.3-6,25 The beneficial 
effect of tolvaptan on kidney growth was ob-
served in all subgroups.
The complications of ADPKD depend on the 
number, size, and location of cysts. A large total 
kidney volume has been associated with hyper-
tension, gross hematuria, nephrolithiasis, and pain 
in many cross-sectional and longitudinal studies.26 
The Consortium for Radiologic Imaging Studies 
of Polycystic Kidney Disease (CRISP) showed that 
total kidney volume as measured with the use of 
MRI predicts functional decline and morbidity, 
supporting its use as a clinically relevant marker of 
progression at early stages of disease.14,15 Never-
theless, the use of total kidney volume as a surro-
gate for treatment efficacy has been questioned.27
We evaluated the effects of tolvaptan on a com-
posite end point of clinically relevant outcomes 
and observed a reduction in events of worsening 
kidney function and kidney pain. The decrease in 
kidney pain occurred early and throughout treat-
ment, possibly reflecting a rapid effect on fluid 
secretion and intracystic pressure,20,21,25 whereas 
the effect on kidney function became evident later, 
given the time required for a patient to have a 
25% reduction in the reciprocal of the serum 
creatinine level. The effect on kidney function 
was nominally greater among patients 35 years 
of age or older and among those with hyperten-
Figure 2 (facing page). Effect of Tolvaptan on the Annual 
Slopes of Total Kidney Volume and Kidney Function.
The slopes of the growth in total kidney volume in the 
intention-to-treat population during the 3-year treatment 
period are shown, with individual patient data included 
in the slope calculations; 6 outliers of the 1315 data 
points in the placebo group and 3 outliers of the 2370 
data points in the tolvaptan group are not shown. The 
ratio of the geometric mean was 0.97 (95% CI, 0.97 to 
0.98; P<0.001) (Panel A). The forest plot of the treat-
ment effect according to baseline subgroups was based 
on the between-group difference in the slopes, with the 
variance approximated by means of the delta method 
under the assumption of independence between the 
slopes. Horizontal bars indicate 95% confidence inter-
vals (Panel B). The slopes of kidney function were  
estimated with the use of the reciprocal of the serum 
creatinine level in the intention-to-treat population dur-
ing the treatment period, and individual patient data 
were included in the slope calculations; 19 outliers of 
4759 data points in the placebo group and 16 outliers 
of 8564 data points in the tolvaptan group are not shown. 
The annual difference in slope was 1.202 (mg per milli-
liter)−1 per year (95% CI, 0.62 to 1.78; P<0.001) (Panel C). 
The forest plot of the treatment effect for kidney function 
according to the baseline subgroups was based on the 
difference in the annual change in slope (with 95% 
confidence intervals) of the reciprocal of the serum 
creatinine level (Panel D).
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sion or a total kidney volume of 1500 ml or more 
at baseline — that is, among patients with more 
advanced disease, who were more likely to have 
functional decline during the relatively short du-
ration of the trial, which is consistent with the 
results of the CRISP study.15
Whether tolvaptan is a helpful long-term treat-
ment in patients with ADPKD will depend on a 
balance between benefits and risks. Adverse events 
consistent with the natural history of ADPKD were 
more frequent among patients who received pla-
cebo than among those who received tolvaptan. 
Some adverse events more common in the tolvap-
tan group were consistent with its aquaretic ef-
fect. Aquaresis-related adverse events led to the 
discontinuation of tolvaptan in approximately 8% 
of participants, mostly within the first month. 
Adverse events related to aquaresis in previous 
clinical trials of tolvaptan for hyponatremia or 
heart failure were similar to those observed in the 
current trial, but the higher frequency of liver-
enzyme elevations was not observed in the previ-
ous trials.28-31
This trial has several limitations. Patients were 
asked to maintain good hydration and avoid thirst. 
In fact, a substantial number of patients in the 
placebo group reported polyuria (17.2%) and noc-
turia (13.0%). Although maintaining hydration 
helped ensure that the blinding in the study was 
maintained, the suppression of vasopressin release 
in the placebo group may have led to an underes-
timation of the beneficial effect of tolvaptan and 
may account for the lower rates of kidney growth 
observed in the placebo group in the current trial, 
as compared with the rates in the control groups 
of previous ADPKD trials (6.8 to 11.8% per 
year).27,32-36 Although patients with near-normal 
kidney function were included in the study, hyper-
tension had already developed in most of these 
patients at baseline, limiting the ability to detect 
a potential beneficial effect of tolvaptan on the 
development or progression of hypertension.
In conclusion, tolvaptan, when given over a pe-
riod of 3 years, slows the increase in total kidney 
volume and the decline in kidney function in pa-
tients with ADPKD. The potential benefit is not 
without risks. Thirst, polyuria, and related adverse 
events may affect the ability of some patients to 
take effective doses of tolvaptan. The potential 
effects on liver-enzyme levels and plasma levels of 
sodium and uric acid require monitoring.
Table 2. Most Common Adverse Events and Serious Adverse Events.*
Event
Tolvaptan 
(N = 961)
Placebo 
(N = 483)
no. of patients with event (%)
Adverse events more common  
in tolvaptan group
Thirst 531 (55.3)† 99 (20.5)
Polyuria 368 (38.3)† 83 (17.2)
Nocturia 280 (29.1)† 63 (13.0)
Headache 240 (25.0) 120 (24.8)
Pollakiuria‡ 223 (23.2)† 26 (5.4)
Dry mouth 154 (16.0) 59 (12.2)
Diarrhea 128 (13.3) 53 (11.0)
Fatigue 131 (13.6) 47 (9.7)
Dizziness 109 (11.3) 42 (8.7)
Polydipsia 100 (10.4)† 17 (3.5)
Adverse events more common  
in placebo group
Hypertension 309 (32.2) 174 (36.0)
Renal pain 259 (27.0)§ 169 (35.0)
Nasopharyngitis 210 (21.9) 111 (23.0)
Back pain 132 (13.7) 88 (18.2)
Increased creatinine level 135 (14.0) 71 (14.7)
Hematuria 75 (7.8)† 68 (14.1)
Urinary tract infection 80 (8.3)§ 61 (12.6)
Nausea 98 (10.2) 57 (11.8)
Serious adverse events more common  
in tolvaptan group
Alanine aminotransferase elevation 9 (0.9) 2 (0.4)
Aspartate aminotransferase elevation 9 (0.9) 2 (0.4)
Chest pain 8 (0.8) 2 (0.4)
Headache 5 (0.5) 0
Serious adverse events more common  
in placebo group
Pyelonephritis 5 (0.5) 5 (1.0)
Renal-cyst infection 6 (0.6) 4 (0.8)
Renal-cyst hemorrhage 3 (0.3) 4 (0.8)
Renal pain 1 (0.1) 4 (0.8)
Appendicitis 1 (0.1) 4 (0.8)
Nephrolithiasis 2 (0.2) 3 (0.6)
Urinary tract infection 1 (0.1) 3 (0.6)
Hypertension 1 (0.1) 3 (0.6)
* Adverse events were categorized according to the Medical Dictionary for Regula­
tory Activities (MedDRA).
† P<0.001 by Fisher’s exact test, as compared with the placebo group.
‡ Pollakiuria is more commonly called urinary frequency.
§ P<0.05 by Fisher’s exact test, as compared with the placebo group.
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